2376137-29-8
Chemical Structure
MS5033
- CAS No.: 2376137-29-8
- Formula:C51H66ClN11O11
- Molecular Weight:1044.59
IUPAC Name: 4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)phenyl)-1-(4-(1-((2S,3S)-2-hydroxypentan-3-yl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)piperazine 1-oxide
InChIKey: CGNFOQWXOLLQAR-JFKYFZFSSA-N
SMILES: O=C1C2=C(NCCOCCOCCOCCOCCOCCC(N3CCN(CC3)CC[C@@H](C4=CC=C(C=C4)Cl)NC(C5(CCN(C6=C7C(NC=C7)=NC=N6)CC5)N)=O)=O)C=CC=C2C(N1C8C(NC(CC8)=O)=O)=O
Biological Activity: MS5033 is a CRBN-recruiting PROTAC degrader that targets AKT1. The IC50 values of MS5033 against human AKT range from 1.3 nM to 798 nM, with Kd values ranging from 4.8 nM to 160 nM. MS5033 inhibits downstream AKT signaling pathways, including the phosphorylation of PRAS40, thereby suppressing cancer cell proliferation and colony formation and inducing cancer cell apoptosis. MS5033 can be used in research on glioma, prostate cancer, triple-negative breast cancer, breast cancer and solid tumors[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MS5033 | MS5033 is a CRBN-recruiting PROTAC degrader that targets AKT1. The IC50 values of MS5033 against human AKT range from 1.3 nM to 798 nM, with Kd values ranging from 4.8 nM to 160 nM. MS5033 inhibits downstream AKT signaling pathways, including the phosphorylation of PRAS40, thereby suppressing cancer cell proliferation and colony formation and inducing cancer cell apoptosis. MS5033 can be used in research on glioma, prostate cancer, triple-negative breast cancer, breast cancer and solid tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lei K, Sheng Y, Li Y, et al. Dynamic Detection of the E3-PROTAC-Target Protein Ternary Complex In Vitro and In Vivovia Bimolecular Fluorescence Complementation[J]. ACS omega, 2024, 9(50): 49739.
- [2]. Yu X, et al. Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of medicinal chemistry. 2022 Oct 27;65(20):14237-14260. [Content Brief]
- [3]. Yu X, et al. Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies. Journal of medicinal chemistry. 2022 Feb 24;65(4):3644-3666. [Content Brief]
- [4]. Bhatt J, et al. PI3K/Akt in IPF: untangling fibrosis and charting therapies. Frontiers in immunology. 2025;16:1549277.
